Protalix BioTherapeutics (PLX) Stock Soars On Data

Protalix Biotherapeutics PLX Stock News

Fabry Disease Is Incredibly Difficult To Treat

Fabry disease is a serious condition that reduces life expectancy in males by more than 15 years. Unfortunately, the condition is incredibly difficult to treat, leading to few options available for patients and their caregivers.

Importantly, the data released today proved to be overwhelmingly positive. When patients switched from the standard of care after at least 2 years of treatment, to PRX-102, meaningful improvements were seen in their condition.

Considering the difficulty associated with treating Fabry disease, and the positive data that was released today, the company is on the right track to developing the next blockbuster therapeutic option in this indication.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Continue Reading

Click below to continue reading!

Pages: 1 2 3 4

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.